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Abstract
Background: Mast cells are well established effectors of IgE-triggered allergic reactions and
immune responses to parasitic infections. Recent studies indicate that mast cells may play roles in
adaptive and innate immunity, suggesting an innovative view of the regulation of immune responses.
Here, we profiled the transcriptome of human mast cells sensitized with IgE alone, or stimulated
by FcεRI aggregation.
Results: Our data show that among 8,793 genes examined, 559 genes are differentially regulated
in stimulated mast cells when compared with resting/unstimulated mast cells. The major functional
categories of upregulated genes include cytokines, chemokines, and other genes involved in innate
and adaptive immune-responses. We observed the increased expression of over 63 gene-
transcripts following IgE-sensitization alone. Our data was validated using Real-Time-PCR; ELISA
and western blot. We confirmed that IgE alone does not trigger mast cell-immediate responses,
such as calcium signals, degranulation or protein-phosphorylation.
Conclusion: This report represents a substantial advance in our understanding of the genome
wide effects triggered by "passive sensitization" or active stimulation of human mast cells,
supporting mast cells' potential involvement in a wide range of inflammatory responses.
Background
Mast cells are best known for their role in immunoglobu-
lin E (IgE)-dependent allergic responses as one of the
most powerful reactions of the immune system [1].
Recent studies suggest that mast cells may also be involved
in innate and adaptive immunity by producing high levels
of chemokines and cytokines [1-3]. Mast cells are derived
from haematopoietic progenitor cells that enter nearly all
vascularized tissues, where they complete their matura-
tion and, in some cases, can migrate into epithelia [1-4].
After appropriate activation, such as the aggregation of the
high affinity IgE receptor (FcεRI), mast cells can produce a
range of pro-inflammatory mediators, including
cytokines and chemokines [5,6]. Crosslinking of FcεRI-
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bound IgE with multivalent antigen initiates the activa-
tion of mast cells by promoting the aggregation of FcεRI
[7,8]. This FcεRI-dependent cell activation process has
three major outcomes: degranulation, secretion of pre-
formed mediators stored in cytoplasmic granules – these
granules contain vasoactive amines, neutral proteases,
proteoglycans and some cytokines and growth factors; the
de novo synthesis of pro-inflammatory lipid mediators
(such as eicosanoids); and the synthesis and secretion of
cytokines and chemokines [4-8].
Mast cells are regarded as key effector cells in IgE-associ-
ated immediate hypersensitivity reactions and allergic
conditions, as well as in certain immune responses to par-
asites [9]. Because the IgE dependent release of proinflam-
matory mediators can begin within minutes of antigen
challenge, the crucial role of mast cells in acute allergic
reactions, such as anaphylaxis and acute attacks of atopic
asthma, is now widely accepted [4,5,7,8]. On the other
hand, the role of mast cells in chronic inflammation and
other long-term tissue changes that are observed in some
IgE associated diseases, including asthma, still debated
[10]. However, in recent studies it is suggested that mast
cells can markedly enhance antigen-dependent airway
hyper reactivity, airway eosinophil infiltration, and the
increased number of proliferating cells in the airway epi-
thelium [11-14]. These reports and other lines of evi-
dence, suggest that a key role of mast cells in IgE-
associated immune responses is to amplify both acute and
long-term local tissue responses to relatively weak biolog-
ical signals [5,9,11,12]. Moreover, through their ability to
release immunoregulatory cytokines, and perhaps
through other mechanisms, mast cells might also influ-
ence the development, strength and persistence of T-
helper 2 cell-associated immunity. However, such immu-
noregulatory functions of mast cells have not been fully
characterized. Mast cells have also been proposed to play
a role in mediating bacterial clearance by releasing
cytokines, and by ingesting and killing opsonized bacte-
ria, suggesting that mast cells have a physiological role in
modulating host defenses against infectious agents [13].
Mast cell products, such as tryptase and histamine, can
influence the immune-response by recruiting neutrophils
or by activating other immune-effector cells [14]. These
previous findings show that mast cells, apart from being
principal players in allergies, appear have effects in the ini-
tiation and regulation of innate immunity. There is
increasing evidence demonstrating that the innate and
adaptive immune systems cooperate through shared sign-
aling mechanisms, and very recently it was shown that
mast cells may regulate the recruitment of T-cells to lymph
nodes [15]. Several groups have carried out limited gene
expression profiles of mast cells, without any stimuli [16-
18]; stimulated by cytokines [19]; triggered by antigens
and in response to the inhibition of calcium-ATPase [20];
or stimulated by TLR4 [21]; or focused on the cytokine/
chemokine profile triggered by FcεRI aggregation [21-23].
A recent study has shown that IgE alone can induce the
release of the interlukin-8 (IL-8) and of the monocyte che-
moattractant protein 1 (MCP-1) [24]. However, many
aspects of the genetic responses triggered by IgE-antigen
on human mast cells are still unclear, such as the overall
genetic responses to IgE sensitization alone, or wide-
genome expression profile triggered by FcεRI aggregation.
Thus, we decided to analyze the differential gene expres-
sion profile of 8,793 fully-annotated genes, after IgE sen-
sitization, and following FcεRI aggregation.
The data we present here show that, over 559 genes were
differentially regulated in the stimulated cells, when com-
pared to unstimulated cells (basal). A substantial number
of genes were regulated by IgE sensitization alone; and fol-
lowing FcεRI aggregation, a wide range of genes were trig-
gered, including genes for cytokines, chemokines,
transcription factors, anti-apoptosis, and several genes
involved in innate and acquired immunity. Some of the
most prominent findings are the upregulation of proin-
flammatory cytokines and chemokines, involved in
innate and adaptive immunity. We also observed the
upregulation of several receptors involved in innate
immune reactions. We confirmed that IgE alone does not
trigger mast cell-immediate responses, such as calcium
signals, degranulation or protein-tyrosine phosphoryla-
tion, whereas FcεRI aggregation did indeed trigger these
immediate responses. Thus, these results represent a sub-
stantial advance in our understanding of the genome-
wide effects triggered by the physiological "passive sensi-
tization" or "active stimulation" of human mast cells, and
suggest that mast cell activation may not only play a piv-
otal role in allergic responses, but may influence the regu-
lation of other inflammatory immune responses.
Results
Generation of mast cells
Perhaps the most important factor for mast cell develop-
ment, survival and proliferation is Stem-Cell Factor (SCF
or c-KIT ligand) [4], although several lines of evidence
also indicate IL-3 as a crucial factor for mast cell develop-
ment, survival and proliferation [4]. Human mast cells are
very difficult to isolate in numbers that would allow for
wide-genome expression profiling studies: for that reason
we isolated CD34+ progenitor hematopoietic cells from
umbilical cord blood and differentiated them to mast
cells by culturing with the cytokines SCF and IL-3. After
culturing CD34+ progenitor cells with cytokines for 5–6
weeks, cells were characterized as Mast Cells by flow
cytometry as positive for the specific mast cell marker
intracellular chymase; positive c-Kit/CD117+ and FcεRI+,BMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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and by Toluidine blue staining (Figure 1). Purity was esti-
mated at >97%.
Differential gene expression profile in stimulated human 
mast cells
Our aim is to study the global gene expression pattern
induced by IgE sensitization and FcεRI aggregation on
human mast cells. Gene expression analysis using cDNA
or oligo-DNA microarrays has proven to be a sensitive
method to develop and refine the molecular determinants
of several human disorders, including cancer and autoim-
mune diseases. We analyzed the expression pattern of
8,793 transcripts from the stimulated mast cells, and com-
pared the expression patterns with control/unstimulated
samples. The complete gene expression data of our exper-
iments, representing 8,793 probeID is available at the
NCBIs Gene Expression Omnibus [25], and is accessible
through GEO Series accession number GSE1933 (25). The
microarray analysis revealed that 760 genes (~8.6%) were
differentially expressed between resting and stimulated
mast cells with statistical significance (P ≤ 0.05), which
were hierarchically clustered (Figure 2). Because of the rel-
atively large number of genes that were differentially reg-
ulated, we focused on genes that were upregulated by at
least a 2-fold in any time point of mast cell stimulation.
Of the 760 genes, 58 genes were initially upregulated (at
least 2-fold) by IgE-sensitization alone (Table. 1), and a
total of 115 genes were overexpressed (by 2-fold or more
in at least one time point), during the time course of mast
cell activation by IgE-alone or after crosslinking FcεRI
(Table. 1). In order to examine the global characteristics of
these genes, we used the Gene Ontology Consortium
database for Biological processes [26]. Using this database
we analyzed the genes that were upregulated by at least 2-
fold, thus, allowing us to separate the 115 genes, into the
following functional families: (a) cytokines and cytokine
receptors; (b) chemokines and chemokine receptors; (c)
other immunoregulatory genes; (d) cell proliferation and
anti-apoptosis; (e) adhesion and cytoskeleton remode-
ling; (f) transcription factors and regulators of transcrip-
tion; (g) signal transduction; (h) genes involved in other
cellular functions "others" (Table 1 & Figure 3)
Upregulation of genes by IgE sensitization
Our study revealed that substantial changes in gene
expression in response to monomeric-IgE sensitization
alone. In order to ensure that the human IgE (IgE, Cat: 30-
AI05, Lot number A01071004, Fitzgerald, Concord, MA),
used in this study was indeed monomeric IgE, prior to
each experiment; we run a sample of the IgE through non-
denaturing polyachrylamide-gel-electrophosys (non-
reducing-PAGE). No aggregates were observed at any time
(data not shown).
We focused the analysis of our data on genes that were
upregulated by at least 2-fold, over basal levels, and iden-
tified 58 genes that were increased by IgE sensitization
alone (Table. 1). We then separated them into different
categories, based on their biological function (determined
by public databases). Among the most prominent find-
ings was the upregulation of genes coding for the
cytokines IL-1β (3.3 fold), IL-6 (2.7 fold), and CSF1 (1.6
fold); genes coding for the chemokines IL-8 (CXCL8) (2.1
fold), MIP1β (CCL4) (3.5 fold), MCP3 (CCL7) (2.1 fold),
GROα (CXCL1) (2.3 fold) and GROγ (CXCL3) (1.6 fold),
were also upregulated. Other than these, several genes
coding for other receptors involved in immune-responses;
immunoregulatory genes; adhesion and/or cytoskeleton
remodeling; regulators of apoptosis; signal transduction;
transcription factors; were also upregulated by mono-
meric IgE (Table. 1). Thus, these results suggest that "pas-
sive" sensitization of mast cells, with monomeric IgE, may
not only prime mast cells to be ready for the challenge to
come, but that mast cells may also have the potential to
Purity of Mast cells Figure 1
Purity of Mast cells. A. Flow cytometry analysis of 
intracellular chymase expression. Human cord blood-
derived mast cells labelled for intracellular mast-cell chymase 
expression (solid line), isotype control (Black area). Results 
shown are representative of four separate experiments. B. 
Toluidine blue staining of mast cells. Fluorescence 
microscopy of human cord blood-derived mast cells stained 
with Toluidine blue. Results shown are representative of at 
least three separate experiments. C. Flow cytometry 
analysis of cell surface expression of c-kit and FcεRI. 
Human cord blood-derived mast cells labelled for cell-surface 
expression of c-kit and FceRI (left panel), and isotype con-
trols (right panel). Results shown are representative of four 
separate experiments.
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trigger the priming and/or recruitment of other immune-
effector cells.
Gene profile of upregulated genes during various time 
points of mast cell stimulation cytokines/cytokine 
receptors and chemokines/chemokine receptors
An interesting finding in our study was upregulation of
genes coding for the pyrogenic and proinflammatory
cytokines IL-1β, IL-6 (Table. 1a). One of the key roles for
IL-1β is to trigger the upregulation of key proinflamma-
tory proteins [27]. We also observed the upregulation of
PTX3 (pentaxin-related gene) (Table. 1c): PTX3 is a pro-
tein involved in inflammation that is rapidly upregulated
by IL-1β. Other cytokine genes that were upregulated are
CSF1 (a growth promoting cytokine), and the cytokine
receptors IL1R1, IL27RA, TNFRSF9, TNFRSF12 and IL1RN
(Table. 1a). We also found that the level of expression of
genes coding for the chemokines IL-8 (CXCL8), CCL7
(MCP3), CCL4 (MIP1β) and CXCL1 (GROα) was
increased (Table 1b). IL-8 plays a major role in inflamma-
tory responses mainly due to its ability to recruit and acti-
vate neutrophils. CCL7, CCL4 and CXCL1 are known to
recruit monocytes, NK, basophils, dendritic cells and TH2
cells. Moreover, our data also show that several other
chemokine genes were upregulated during mast cell stim-
ulation: these include CCL5 (RANTES), CXCL3 (GROγ),
and the chemokine receptor CCRL2 (Table. 1b). These
data suggest a key role for FcεRI in triggering an a wide
range of inflammatory responses, as the over-expression
of cytokines and chemokines is a prerequisite to triggering
inflammation, including vascular permeability, and leu-
kocyte and lymphocyte recruitment, differentiation and
activation.
Other immune-regulatory genes
Several genes involved in innate and adaptive immune-
response were upregulated at least by 2-fold during mast
cell stimulation: these include the Toll Like Receptor 2
(TLR2), as well as several genes of the TNFα signaling
pathways, including TNFAIP6 (Table. 1c). These findings
support previous reports of the role of mast cells in innate
immunity and antibacterial activity [21]. Transcripts of
genes LIF, CD69, and CD83 were also upregulated, as were
the major histocompatibility complex genes (HLA-DQB1,
and  HKE2) and inhibitory receptor of IgG, FCGR2B
(Table. 1c). The generation of transcripts for such genes
suggests that mast cells can acquire characteristics typical
of cells involved in innate and adaptive immune
responses.
Cell proliferation and anti-apoptosis
Several genes involved in cell proliferation and survival,
such as PDGFA  (platelet-derived growth factor alpha
polypeptide), PDGFB (platelet-derived growth factor beta
polypeptide),  PBEF1  (pre-B-cell colony-enhancing fac-
tor), TIEG (TGFB inducible early growth response), and
INSIG1  (insulin induced gene 1) were upregulated, as
well as several anti-apoptosis genes including TNFAIP3
Changes in gene expression in human mast cells following IgE  sensitization and FcεRI aggregation Figure 2
Changes in gene expression in human mast cells fol-
lowing IgE sensitization and FcεRI aggregation. 
Changes in expression over control of human cord blood 
derived mast cells that were activated by IgE sensitization and 
FcεRI crosslinking for different time points (2 hr, 6 hr and 12 
hr). Labelled cRNA from cell of each time point were hybrid-
ized to Human Genome Focus array and signals were 
scanned after fluidics. The data was analyzed as described in 
material and methods and analysis revealed differential 
expression of 760 genes between resting and stimulated mast 
cells with statistical significance (P ≤ 0.05). Agglomerative 
average-linkage hierarchical clustering of the five different 
experimental conditions was obtained for selected groups of 
genes using GeneSpring 7.0. Each colored box represents the 
normalized expression level of a given gene in a particular 
experimental condition and is colored according to the color 
bar. The data represent average of four independent experi-
ments.
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Table 1: Differentiated, human cord blood-derived, mast cells were sensitized overnight by the addition of monomeric IgE followed by 
crosslinking the high affinity IgE receptors, FcεRI using anti IgE for 2 h, 6 h and 12 h. Gene expression profile at each time point were 
analyzed and 115 genes, which were upregulated 2 fold or more (over control/unstimulated cells) atleast in one point have been 
selected and classified according to their biological functions as a) Cytokines and cytokine receptors b) Chemokine and chemokine 
receptors c) Other immunoregulatory genes d)Cell proliferation and anti-apoptosis e)Adhesion and cytoskeleton remodeling 
f)Transcription factors and regulators g) Signal transduction h) Other genes. Fold change is expressed as fold-increase over control/
unsensitized samples, and representative of four separate experiments.
a. Cytokines and cytokine receptors
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
M15330 IL1B Interleukin 1, beta 3.3 4.8 1.5 -2.0
NM_000600.1 IL6 Interleukin 6 2.0 2.6 1.9 -1.3
M37435 CSF1 Colony stimulating factor 1 1.6 4.5 1.9 -1.4
NM_000877.1 IL1R1 Interleukin 1 receptor, type I 1.4 2.2 1.9 -1.2
AI983115 IL27RA Class I cytokine receptor 1.4 1.3 2.6 1.1
NM_001561.2 TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 1.2 1.5 2.5 1.7
NM_016639.1 TNFRSF12A Tumor necrosis factor receptor superfamily, member 12A 1.5 2.4 -1.3 -1.9
X52015 IL1RN Interleukin 1 receptor antagonist 1.1 2.4 2.6 1.4
b. Chemokine and chemokine receptors
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
NM_002984.1 CCL4 Chemokine (C-C motif) ligand 4 3.5 4.7 1.6 -3.0
NM_001511.1 CXCL1 Chemokine (C-X-C motif) ligand 1 2.3 2.5 1.1 -2.9
NM_006273.2 CCL7 Chemokine (C-C motif) ligand 7 2.1 3.6 5.3 2.2
NM_002090.1 CXCL3 Chemokine (C-X-C motif) ligand 3 1.6 2.5 1.6 -1.8
NM_002985.1 CCL5 Chemokine (C-C motif) ligand 5 1.6 1.8 2.1 1.8
AF015524 CCRL2 Chemokine (C-C motif) receptor-like 2 1.5 2.0 2.0 1.2
AF043337 IL8 Interleukin 8 2.1 2.1 1.5 -1.5
c. Other immunoregulatory genes
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
S59049 BL34 B cell activation gene 3.4 6.8 -2.3 -3.9
NM_002309.2 LIF Leukemia inhibitory factor (Cholinergic differentiation factor) -1.3 5.1 -1.3 -4.0
L07555 CD69 CD69 antigen -1.1 4.1 -1.0 -1.7
AF036906 LAT Linker for activation of T cells 1.9 2.3 2.3 1.7
NM_004233.1 CD83 CD83 antigen 2.4 3.0 1.6 -1.2
NM_000675.2 ADORA2A Adenosine A2a receptor 2.1 3.8 1.4 -1.3
NM_001311.1 CRIP1 Cysteine-rich protein 1 1.5 2.6 2.7 1.3
M16276 HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 1.9 2.0 1.7 1.2
AW007185 HKE2 HLA class II region expressed gene KE2 1.4 1.4 2.2 1.9
NM_005658.1 TRAF1 TNF receptor-associated factor 1 1.5 2.5 1.8 -1.0
NM_005601 NKG7 Natural killer cell group 7 sequence 1.4 2.2 1.3 1.3
NM_002852.1 PTX3 Pentaxin-related gene, rapidly induced by IL-1 beta 1.8 2.5 1.5 -2.1
M31933 FCGR2B Fc fragment of IgG, low affinity IIb, receptor for (CD32) 2.0 2.0 1.3 -1.1
NM_007115.1 TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 2.0 2.4 2.1 -1.1
NM_000956.1 PTGER2 Prostaglandin E receptor 2 (subtype EP2) 2.0 2.2 1.3 -1.5
NM_013252.1 CLECSF5 C-type lectin, superfamily member 5 1.6 2.3 2.5 1.2
NM_004951.1 EBI2 Epstein-Barr virus induced gene 2 (lymphocyte-specific GPCR) 1.4 2.0 -1.7 -2.0
NM_018643.1 TREM1 Triggering receptor expressed on myeloid cells 1 1.4 2.2 2.5 1.7
U37546 BIRC3 Baculoviral IAP repeat-containing 3 1.4 2.0 1.1 -1.1
NM_002000.1 FCAR Fc fragment of IgA, receptor for 1.4 2.0 1.7 -1.9
NM_003264.1 TLR2 Toll-like receptor 2 1.4 2.0 2.0 -1.6
NM_002114.1 HIVEP1 Human immunodeficiency virus type I enhancer binding protein 1 2.0 1.6 -1.2 -1.6
d. Cell proliferation and anti-apoptosisBMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
NM_006732.1 FOSB FBJ murine osteosarcoma viral oncogene homolog B 2.1 3.9 -3.0 -4.9
NM_004430.1 EGR3 Early growth response 3 1.8 7.5 -1.4 -3.3
AF001294 PHLDA2 Tumor suppressing subtransferable candidate 3 2.6 3.8 1.7 -1.2
NM_002575.1 SERPINB2 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 1.9 3.8 5.2 -1.1
M60485 FGFR1 Ffibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer 
syndrome)
2.3 2.2 2.7 1.5
NM_000399.2 EGR2 Early growth response 2 (Krox-20 homolog, Drosophila) 1.6 2.7 1.6 -1.9
NM_005542.3 INSIG1 Insulin induced gene 1 1.7 2.8 1.6 -1.2
NM_002607.1 PDGFA Platelet-derived growth factor alpha polypeptide 1.8 2.4 1.7 1.1
NM_003897.1 IER3 Immediate early response 3 1.8 3.0 -1.2 -2.3
NM_002608.1 PDGFB Platelet-derived growth factor beta polypeptide 1.2 2.0 -1.2 1.0
NM_006763.1 BTG2 BTG family, member 2 1.5 2.0 -1.1 -1.9
NM_005655.1 TIEG TGFB inducible early growth response 1.8 1.9 -1.8 -2.4
NM_004073.1 CNK Cytokine-inducible kinase 1.2 1.8 -1.5 -2.4
BF575514 PBEF1 Pre-B-cell colony-enhancing factor 1.6 1.9 -1.3 -3.2
NM_006290.1 TNFAIP3 TNF-induced protein 3 2.7 3.4 1.8 -1.0
BC005352 TNFAIP8 TNF-induced protein 8 2.0 1.6 1.3 1.3
NM_023009.1 MLP MARCKS-like protein 1.5 1.7 2.5 1.1
NM_001878.2 CRABP2 Cellular retinoic acid binding protein 2 1.1 1.2 1.4 2.0
NM_002199.2 IRF2 Interferon regulatory factor 2 -1.5 -1.7 1.2 2.0
e. Adhesion and cytoskeleton remodeling
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
NM_004658.1 RASAL1 RAS protein activator like 1 (GAP1 like) 2.2 2.2 3.6 2.3
NM_013231.1 FLRT2 Fibronectin leucine rich transmembrane protein 2 1.4 2.3 2.3 2.4
NM_003078.1 SMARCD3 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily d, member 3
2.2 1.9 1.2 1.1
BG054844 ARHE Ras homolog gene family, member E 1.3 2.2 1.9 -1.0
NM_000216.1 KAL1 Kallmann syndrome 1 sequence 1.4 1.4 1.3 2.0
M62994 FLNB Filamin B, beta (actin binding protein 278) 1.2 1.4 2.0 1.0
NM_004357.1 CD151 CD151 antigen 1.0 1.2 2.1 -1.1
AA243143 ARF6 ADP-ribosylation factor 6 2.1 1.3 1.1 1.0
NM_001627.2 ALCAM Activated leukocyte cell adhesion molecule 1.1 1.1 1.7 2.0
f. Transcription factors and regulators
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
AL021977 MAFF V-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 2.6 6.3 1.2 -2.2
AF060154 MSC Musculin (activated B-cell factor-1) 1.8 2.4 1.9 1.1
M55643 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 1.7 2.1 1.5 -1.0
NM_001706.1 BCL6 B-cell CLL/lymphoma 6 2.4 2.0 1.5 1.2
U08015 NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 1.3 2.3 -1.1 -1.1
NM_001674.2 ATF3 Activating transcription factor 3 1.3 2.0 -1.0 -1.6
AI078167 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha
1.9 2.0 1.3 -1.5
NM_004556.1 NFKBIE Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
epsilon
1.7 2.0 1.1 -1.2
NM_002467.1 MYC V-myc myelocytomatosis viral oncogene homolog (avian) 1.7 2.1 1.1 -1.3
NM_001423.1 EMP1 Epithelial membrane protein 1 1.4 1.6 2.1 1.3
NM_012081 ELL2 ELL-related RNA polymerase II, elongation factor 1.7 1.3 2.6 1.3
NM_001067.2 TOP2A Topoisomerase (DNA) II alpha 170kDa 2.0 1.0 1.2 1.3
Table 1: Differentiated, human cord blood-derived, mast cells were sensitized overnight by the addition of monomeric IgE followed by 
crosslinking the high affinity IgE receptors, FcεRI using anti IgE for 2 h, 6 h and 12 h. Gene expression profile at each time point were 
analyzed and 115 genes, which were upregulated 2 fold or more (over control/unstimulated cells) atleast in one point have been 
selected and classified according to their biological functions as a) Cytokines and cytokine receptors b) Chemokine and chemokine 
receptors c) Other immunoregulatory genes d)Cell proliferation and anti-apoptosis e)Adhesion and cytoskeleton remodeling 
f)Transcription factors and regulators g) Signal transduction h) Other genes. Fold change is expressed as fold-increase over control/
unsensitized samples, and representative of four separate experiments. (Continued)BMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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AF078847 GTF2H2 General transcription factor IIH, polypeptide 2, 44kDa -1.0 1.1 2.0 -1.1
g. Signal transduction
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
NM_004418.2 DUSP2 Dual specificity phosphatase 2 4.3 7.2 1.8 1.5
NM_000361.1 THBD Thrombomodulin 2.5 4.5 1.0 -1.7
S77154 NR4A2 Nuclear receptor subfamily 4, group A, member 2 1.3 4.1 -1.0 -2.1
NM_005261.1 GEM GTP binding protein overexpressed in skeletal muscle 1.2 2.7 1.1 -1.1
AF035776 OLR1 Oxidised low density lipoprotein (lectin-like) receptor 1 2.0 2.6 3.1 -1.0
NM_000161.1 GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia) 2.0 2.4 1.7 -1.9
NM_021972.1 SPHK1 Sphingosine kinase 1 1.4 2.1 2.7 -1.0
NM_005001.1 NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa 1.6 1.6 2.0 1.4
M60278 HBEGF Heparin-binding EGF-like growth factor 1.1 2.4 -2.1 -5.0
U77914 JAG1 Jagged 1 (Alagille syndrome) 1.4 2.5 1.8 1.0
NM_000527.2 LDLR Low density lipoprotein receptor 1.6 2.0 -1.8 -1.4
NM_005904.1 MADH7 MAD, mothers against decapentaplegic homolog 7 (Drosophila) 1.7 1.9 -1.2 -2.0
AF070528 MALT1 Mucosa associated lymphoid tissue lymphoma translocation gene 1 1.5 2.1 1.2 -1.2
NM_005842.1 SPRY2 Sprouty homolog 2 (Drosophila) 1.1 2.2 1.4 -1.3
BC003143 DUSP6 Dual specificity phosphatase 6 1.2 2.2 1.2 -1.4
AA780381 MAP2K3 Mitogen-activated protein kinase kinase 3 -1.0 2.1 -1.0 -1.7
NM_001881.1 CREM cAMP responsive element modulator 1.2 2.0 -1.0 -1.1
NM_004417.2 DUSP1 Dual specificity phosphatase 1 1.6 1.8 -2.3 -3.3
NM_003954.1 MAP3K14 Mitogen-activated protein kinase kinase kinase 14 1.5 2.0 1.3 1.4
AF305083 FUT4 Fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific) 2.0 1.6 1.2 -1.5
BE327172 JUN V-jun sarcoma virus 17 oncogene homolog 1.7 1.5 1.4 2.0
L06633 PSCDBP Pleckstrin homology, Sec7 and coiled/coil domains, binding protein 1.3 1.6 2.0 1.1
M14333 FYN FYN oncogene related to SRC, FGR, YES 1.3 1.5 3.7 1.6
NM_005023.1 PGGT1B Protein geranylgeranyltransferase type I, beta subunit 1.7 1.4 1.5 2.1
NM_006296.1 VRK2 Vaccinia related kinase 2 1.3 1.4 2.0 -1.1
AF127481 proto-LBC A kinase (PRKA) anchor protein 13 1.4 -1.1 1.3 2.0
NM_003318.1 TTK TTK protein kinase 1.6 -1.1 2.1 1.6
h. Other genes
Genbank ID Gene symbol Gene name IgE Sens 2 h 6 h 12 h
NM_003633.1 ENC1 Ectodermal-neural cortex (with BTB-like domain) 2.2 3.1 1.1 1.4
NM_004694.1 SLC16A6 Solute carrier family 16 (monocarboxylic acid transporters), member 6 2.6 2.5 1.0 1.4
AA451996 HIST2H2AA H2A histone family, member O 2.3 2.4 2.4 1.4
AF182273 CYP3A4 Cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4 1.2 2.0 1.0 1.1
BC002649 HIST1H1C Histone 1, Hic 2.1 1.8 2.0 1.7
NM_006101.1 HEC Highly expressed in cancer, rich in leucine heptad repeats 2.3 1.3 2.1 1.6
NM_004760.1 STK17A Serine/threonine kinase 17a 1.4 1.8 2.0 -1.1
NM_020651.2 PELI1 Pellino homolog 1 (Drosophila) 2.2 1.4 1.4 1.0
L39833 KCNAB1 Potassium voltage-gated channel, shaker-related subfamily, beta member 1 2.4 1.4 1.1 1.4
BF223021 B4GALT4 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 4 2.0 1.2 1.5 1.2
Table 1: Differentiated, human cord blood-derived, mast cells were sensitized overnight by the addition of monomeric IgE followed by 
crosslinking the high affinity IgE receptors, FcεRI using anti IgE for 2 h, 6 h and 12 h. Gene expression profile at each time point were 
analyzed and 115 genes, which were upregulated 2 fold or more (over control/unstimulated cells) atleast in one point have been 
selected and classified according to their biological functions as a) Cytokines and cytokine receptors b) Chemokine and chemokine 
receptors c) Other immunoregulatory genes d)Cell proliferation and anti-apoptosis e)Adhesion and cytoskeleton remodeling 
f)Transcription factors and regulators g) Signal transduction h) Other genes. Fold change is expressed as fold-increase over control/
unsensitized samples, and representative of four separate experiments. (Continued)BMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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(TNF-alpha-induced protein 3), TNFAIP8  (TNF-alpha-
induced protein 8), IER3 (immediate early response 3),
SERPINB2 (serine or cysteine proteinase inhibitor B2),
and IRF2 (interferon regulatory factor 2) (Table. 1d). This
supports the fact that, in the initial stages of mast cell acti-
vation, several mediators produced are mainly for cell
proliferation and survival [28]. Thus, FcεRI aggregation
may enhance mast cell proliferation and survival, perhaps
owing to the autocrine effects of the cytokines, growth fac-
tors, and antiapoptotic proteins, triggered by FcεRI aggre-
gation.
Cell adhesion and cytoskeleton remodeling
Another functional characteristic of immune-cell activa-
tion is the coordinated expression of genes involved in
cell adhesion and cytoskeleton remodeling (Table. 1e). Of
particular importance are the genes coding for proteins
involved in cell motility, cytokinesis, endocytosis and exo-
cytosis. We found at least 2-fold upregulation of various
genes coding for proteins involved in cell adhesion, such
as FLRT2 (fibronectin leucine rich transmembrane pro-
tein 2), KAL1 (Kallmann syndrome 1 sequence), CD151
(CD151 antigen), and ALCAM (activated leukocyte cell
adhesion molecule); as well as for several gene-transcripts
involved in cytoskeleton remodeling, including RASAL1
(RAS protein activator like 1), ARHE (RAS homolog gene
family, member E), ARF6  (ADP-ribosylation factor 6),
and FLNB (filamin B, β-actin binding protein 278) (Table.
1e). The expression of genes involved in cell adhesion and
cytoskeleton remodeling is an essential step in immune-
cell activation. Resting immune cells have cytoskeletal
structures that sequester antigen, chemokine, and adhe-
sion receptors in accessible regions of the plasma mem-
brane. Upon activation, reorganization of the actin
cytoskeleton leads to the formation of supramolecular
activation clusters, bringing receptors and costimulatory
molecules together, as well as important adaptor proteins
that promote the sustained activation of the cell.
Transcription factors and regulators of transcription
Stimulation of immune-effector cells through their anti-
gen receptors initiates cell cycle entry and changes the
gene expression pattern, a response generally referred to as
"activation". We found that the genes for several transcrip-
tion factors were upregulated during IgE-sensitization and
FcεRI aggregation, including the transcription factors
most active during an immune response, such as NFκB
and NFAT (Table. 1f). We observed an increase in the
transcripts for the nuclear factor of kappa light polypep-
tide genes 1, alpha, and epsilon (NFκB 1, 1A, and 1E), and
Pie chart showing the percentage distribution of the upregulated genes Figure 3
Pie chart showing the percentage distribution of the upregulated genes. A. Percentage distribution of the total 
amount of genes upregulated. All the genes, observed to be upregulated at least 2-fold at any given time point, were dis-
tributed, according to their biological function described in table 1. B. Percentage distribution of genes upregulated by 
IgE alone. Distribution, according to biological function, of the genes observed to be upregulated during IgE sensitization (IgE 
alone).
Cytokines and cytokine receptors
Chemokines and chemokines receptors
Other immune regulatory genes
Cell proliferation and anti-apoptosis
Adhesion and cytoskeleton remodeling
Transcription factors/regulators of transcription
Signal transduction
Other genes
7%
5%
21%
16%
8%
11%
23%
9%
Distribution of all upregulated genes into
functional families as % of the total 100%
A
15%
17%
11%
4% 14%
27%
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6%
Distribution of genes upregulated by IgE alone
into functional families as % of the total 100%
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the nuclear factor of activated T cells, NFATC1 (Table. 1f).
Other transcription factors upregulated were the onco-
genes  MYC  (v-myc myelo-cytomatosis viral oncogene
homolog), and MAFF (v-maf musculo-aponeurotic fibro-
sarcoma oncogene homolog F) (Table. 1f). Interestingly,
the activities of NFκB and NFAT together are responsible
for the transcription of many proinflammatory genes,
including several genes coding for cytokines and chemok-
ines [29,30].
Signal transduction
During mast cell activation, many signaling molecules are
engaged in diverse responses, ranging from calcium
release from internal stores, degranulation, the generation
of lipid-derived proinflammatory mediators and the pro-
duction of cytokines and chemokines. In our study we
observed that a substantial number of genes coding for
intracellular signaling proteins were upregulated, by at
least 2-fold (Table. 1g). These include genes for serine pro-
tein kinases of the Mitogen Activated Protein Kinase fam-
ily, such as MAP2K3  and  MAP3K14: members of this
family of kinases not only play a role in mitogenesis, but
can potentially lead to the activation of transcription fac-
tors. The gene coding for the tyrosine kinase FYN (FYN
oncogene related to SRC, FGR, YES) was also upregulated
(Table. 1g): FYN is a member of the Src-tyrosine kinase
family; members of this family are critical for the signal
transduction cascades triggered by all antigen receptors
including by FcεRI, TCR, FcγRs, and the B-cell antigen
receptor. Several genes coding for protein phosphatases
were also upregulated, including several members of the
dual specificity phosphatase family coding for DUSP1,
DUSP2, and DUSP6 (Table. 1g). Moreover, we show here
the upregulation of genes that code for oxidized low den-
sity lipoprotein receptor (OLR1), and for the low density
lipoprotein receptor (LDLR) (Table. 1g), indicating a
potential role for mast cells in cholesterol homeostasis. Of
particular interest is the upregulation of the gene coding
for the lipid kinase, sphingosine kinase 1 (SPHK1) (Table.
1g). We and others have previously reported that SPHK1
plays a critical role in the intracellular signaling pathways
triggered by FcεRI in mast cells [28,31], and coordinates
several physiological responses triggered by activated
mast cells.
Real time PCR
We confirmed our microarrays findings by Real time PCR
on selected genes such as IL-1β IL6, IL-8, MCP3, RANTES
and SPHK1, utilizing an aliquot of the same RNA sample
that was used for the microarray experiments (Figure 4).
The results showed that the messenger RNA for the
selected genes follows a similar pattern of expression to
that observed with the oligo-DNA microarray experiment,
thus confirming the results and the quality of the data
obtained with the high-density microarrays.
Protein expression by ELISA
Mast cell activation also results in the sustained de novo
production of pro-inflammatory cytokines and chemok-
ines both of which may contribute to the inflammation
and pathology underlying allergic disease as well as in
innate and acquired immunity. The amounts of these
cytokines were measured by ELISA and depicted in Figure
5A. FcεRI-triggered generation of IL-1β, IL-6, IL-8, CCL7
(MCP3) and CCL5 (RANTES), whereas IgE sensitization
alone triggered smaller amounts of IL-1β and MCP3, high
amount of IL-8, and very less amounts of IL-6 and
RANTES (Figure 5A).
Protein expression by Western blot
We verified the differential expression of SPHK1 by West-
ern blot analysis (Figure 5B). Its levels of expression were
found to be consistent with that of microarray as well as
Real Time PCR results. Thus, these data together with Real
Time PCR data validate microarray results.
Mast cells show strong activation by FcεRI aggregation but 
not by IgE-sensitization
Mast cell activation via FcεRI triggers exocytosis of gran-
ules containing pre-formed inflammatory mediators in a
tyrosine kinase and calcium dependent manner. Here we
studied, whether monomeric-IgE alone, may activate
FcεRI intracellular signaling pathways, leading to physio-
logical responses of mast cells, by analyzing the overall
tyrosine phosphorylation; fluctuations in cytosolic Ca2+
concentration; and degranulation by measuring β-hex-
osaminidase release (Fig. 6A,B &6C). We show here that
in our experimental setting monomeric-IgE alone is not
able to trigger any changes on the overall protein-tyrosine
phosphorylation patterns compared with resting cells; nor
was it able to trigger calcium release from internal stores;
neither degranulation. On the other hand FcεRI-aggrega-
tion did indeed trigger all these responses (Fig. 6A,B &6C).
Discussion
Binding of IgE to FcεRI enhances the cell surface expres-
sion of FcεRI, as a result, its ability to promote the stabili-
zation/accumulation of FcεRI on the mast cell surface in
the presence of continued basal levels of protein synthesis
[32,33]. It is possible that most of the enhanced IgE
dependent functions that are observed after antigen or
anti-IgE-induced FcεRI aggregation, in cells that have been
sensitized with IgE, are a consequence of the higher level
of FcεRI expression. However, a controversial question
remains as to whether monomeric IgE can also have more
direct effects on mast cell functions. Many studies over the
years have shown no evidence that the binding of mono-
meric IgE can induce detectable signaling or production of
mediators by mast cells. However, some groups have
reported that monomeric IgE can enhance mast cell sur-
vival and trigger cytokine production [24,28,33]. In con-BMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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Real-Time PCR of selected genes Figure 4
Real-Time PCR of selected genes. Comparison of gene expression from control/resting mast cells (Con); after mast cells 
were sensitized by human IgE (Sen), and following a time course of FcεRI aggregation for 2 hours (2 h), 6 hours (6 h) and 12 
hours (12 h). 1 µg of total RNA was used from the same sample which has been used for microarray experiments at different 
time points for Light-Cycler Real-Time PCR. The concentrations of these transcripts were calculated using respective standard 
curves. (A) IL-1β expression; (B) IL-6 expression; (C) IL-8 expression; (D) MCP3 expression; (E) RANTES expression; and (F) 
SPHK1 expression. The data represent average ± the standard deviation of four different samples.
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trast, a recent study by Matsuda et al [24], fail to find any
ability of IgE to enhance mast cell survival on withdrawal
of SCF. Interestingly, the study by Matsuda et al, also
showed that IgE sensitization alone can induce the upreg-
ulation of cytokines and chemokines at the protein level,
namely IL-8 and MCP1 [24]. In agreement to this, we
show that IL-8 is induced by IgE alone at the mRNA as
well as at the protein level (table 1, and Figures 4 and 5),
in contrast we could not detect any significant increment
on MCP-1 levels, we can speculate that this difference
could be due to the different amounts IgE used (1 µg/mL
vs 2.5 µg/mL). However, we also show the upregulation of
various chemokines, including the MCP-1-related protein
MCP-3, which was also upregulated by IgE alone (table 1,
and Figures 4 and 5). In our present study, we found that
several genes related to proliferation were upregulated by
IgE alone (Table 1); however, whether these genes, if fully
transcribed, may be able to trigger mast cell proliferation
in the absence of SCF is not known.
The observation that IgE alone can induce the upregula-
tion of a substantial number of genes encoding for
cytokines and chemokines, has profound implications in
our understanding of the role of mast cell in inflamma-
tion. Cytokines and chemokines share many activities,
including the ability to induce fever and shock syndrome
in animal models [27]. Cytokine and chemokine produc-
tion are universal components of a wide range of disease
states, including immune-complex-mediated conditions
such as nephritis [34], arthritis [35], and acute graft rejec-
Protein expression analysis Figure 5
Protein expression analysis. A. ELISA for selected Cytokines and Chemokines. Cytokine and chemokine genera-
tion/release was determined from control-unstimulated mature mast cell (Basal); following IgE-sensitization (IgE) for 24 hours; 
and FcεRI aggregation by addition of the anti-human IgE to sensitized cells for 24 hours (XLFcεRI). Cell culture supernatants 
were analyzed for bioactive IL-1β; IL-6; IL-8; MCP-3 and RANTES by ELISA. Results shown are the mean plus the standard 
deviation of triplicate measurements and are representative of four separate experiments. B. Western Blot analysis of 
SPHK1. Upper panel; differential expression of SPHK1 was assessed by Western blot on lysates from control unstimulated 
cells (Basal); following IgE-sensitization (IgE) for 24 hours; and FcεRI aggregation by addition of the anti-human IgE to sensitized 
cells for 24 hours (XLFcεRI). Lower panel; the blots were probed for α-tubulin (control for equal loading). Results shown are 
representative of four separate experiments.
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tion [36]. These data suggest a potential role for mast cells
in triggering, or at least contributing to, strong inflamma-
tory responses.
In is also interesting to mention that, several genes encod-
ing for transcription factors were upregulated by mono-
meric-IgE and FcεRI aggregation. Perhaps the most
prominent of these transcription factors, is NFκB. NFκB
represents a family of related proteins which dimerize to
form transactivating complexes [35]. NFκB dimmers are
sequestered in the cytoplasm by interaction with inhibi-
tory proteins (the IκBs). Various stimuli activate kinase
signaling cascades that result in the phosphorylation and
degradation of IκB, thereby releasing NFκB to translocate
to the nucleus, where it activates transcription of target
genes. Many studies have emphasized the role of this tran-
scription factor in regulating genes at critical points in
immune-cell development and activation [37]. Many
NFκB targets are antiapoptotic [38], which may explain
the importance of the NFκB pathway in oncogenesis and
resistance to chemotherapy [39,40]. During an immune-
response several genes are triggered by the NFκB, these
include genes coding for the various proinflammatory
molecules, such as MIPs, IL-1β, IL-6, IL-8, TNFα, GROα
and other cytokines, chemokines and cell adhesion mole-
cules ICAM, VCAM and selectins [41].
As immune cells progress through development and
respond to antigenic challenge, they trigger signal trans-
duction pathways that alter their cellular functions and
the activity of transcription factors, changing their effector
functions and their gene expression profiles. During mast
cell activation, many signaling molecules are engaged in
diverse responses, ranging from calcium release from
internal stores, degranulation, the generation of lipid-
derived proinflammatory mediators and the production
of cytokines and chemokines. In our study we observed
that a substantial number of genes coding for intracellular
signaling proteins were upregulated, by at least 2-fold,
during mast cell stimulation (Table. 1g). Interestingly, we
observed a substantial upregulation of the mRNA for
sphingosine kinase 1 (SPHK1), even by IgE alone, this
upregulation was also confirmed at the protein level.
Sphingosine kinases are novel enzymes that phosphor-
ylate sphingosine (a membrane lipid), to generate the
bioactive molecule sphingosine-1-phosphate (SPP),
which is implicated in several inflammatory responses.
We and others have previously reported that SPHK1 plays
a critical role in the intracellular signaling pathways trig-
gered by FcεRI in mast cells [28,31], and coordinates sev-
eral physiological responses triggered by activated mast
cells. We showed that SPHK1 is involved in the calcium
signals triggered by FcεRI aggregation in human mast
cells, as well as playing a critical role for mast cell degran-
ulation [31]. Previously, we reported a pivotal role for
Mast cell activation: tyrosine phosphorylation, calcium sig- nals, degranulation Figure 6
Mast cell activation: tyrosine phosphorylation, cal-
cium signals, degranulation. A. Analysis of overall 
protein phosphorylation on tyrosine residues. Upper 
panel; overall tyrosine-phosphorylation pattern was analysed 
in cell extracts from: control unstimulated cells (Basal); cells 
treated with IgE alone for (IgE) for 5 min; and after FcεRI 
crosllinking for 5 min (XLFcεRI). Lower panel; the blots were 
probed for α-tubulin (control for equal loading). Results 
shown are representative of four separate experiments. B. 
Levels of intracellular free calcium. Intracellular calcium 
measurements of mast cells following addition of IgE alone 
(IgE); and following the addition of the anti-human IgE, to IgE-
sensitized cells (XLFcεRI), the intracellular calcium levels 
were analyzed in a continuous reading for the timesstated in 
the graph. Results shown are the mean plus the standard 
deviation of triplicate measurements and are representative 
of four separate experiments. C. Degranulation. B-hex-
osaminidase release was determined from control-unstimu-
lated mast cells (Basal); following monomeric-IgE-
sensitization for 30 minutes (IgE); and following FcεRI aggre-
gation by addition of the anti-human IgE to sensitized cells for 
30 minutes (XLFcεRI). Results shown are the mean plus the 
standard deviation of triplicate measurements and are repre-
sentative of four separate experiments.
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SPHK1 in monocyte activation by the high-affinity IgG
receptor (FcγRI) [42,43], showing that SPHK is key in trig-
gering calcium release from internal stores, and the activa-
tion of the phagocyte NADPH oxidase. Moreover, very
recently we demonstrated the role of SPHK1 in inflamma-
tory responses triggered by the anaphylatoxin C5a in
human neutrophil and macrophages. These responses
include: calcium signals, degranulation, cytokine produc-
tion and chemotaxis triggered by C5a [44,45]. The obser-
vation that the gene encoding for SPHK1 is activated
during IgE-sensitization of mast cells, coupled to the find-
ings above may indicate a key role for SPHK1 in mast cell
triggered responses.
The significance of this research supports the notion that,
activation of mast cells appear to be linked to a wide range
of pathologies, not only in allergies (as is widely recog-
nized), but potentially in other inflammatory conditions.
The method of global gene expression analysis using
cDNA or oligo-DNA microarrays has proven to be a sensi-
tive method to identify and define/redefine the molecular
determinants of several human disorders, including can-
cer and autoimmune diseases, and has provided us with
signatures of the immune response [41]. Using this tech-
nology, complemented with powerful analytical meth-
ods, we compared the gene expression profiles of human
mast cells stimulated by IgE sensitization, and from a
series of time points of FcεRI aggregation, with unstimu-
lated/control human mast cells. Whether changes in gene
expression, under these conditions, are representative of a
pathological state is not currently known. It is also not
known whether IgE/antigen and FcεRI aggregation will
trigger the same set of genes in an organism, where a
number of events may be activating mast cells at the same
time. However, taken together, our data brings us better
insights into the molecular basis of mast cell activation,
and provides meaningful information, regarding the
mechanisms by which mast cell activation may contribute
to the overall activation of the immune response, having
clinical implication for improving not only allergic condi-
tions but potentially other inflammatory diseases, where
mast cells may play a role.
Conclusion
This study is an attempt to elucidate the molecular mech-
anisms which mast cells undergo during "priming" IgE
sensitization and full activation by FcεRI aggregation in a
global perspective. In conclusion, our present study pro-
vides information that mast cells, by generating a broad
range of cytokines and chemokines, may be a potent con-
tributor of the immune response by recruiting and/or acti-
vating other immune-effector cells including the
activation of lymphocytes that may, in turn, continue the
spreading of the inflammatory response. Moreover,
changes in the gene expression pattern of transcription
factors, intracellular signaling molecules, and cytoskeletal
remodeling and anti-apoptosis pathways occur, which
would also contribute to the amplification of the inflam-
matory response. Mast cells are well established innate
immune-effector cells, and there is mounting evidence to,
at least, suggest that mast cells may contribute to the
development of acquired immunity [46,47], whether in
host defense or in allergic or autoimmune diseases. It will
be pivotal to define in more detail whether and under
which circumstances mast cells may influence the devel-
opment and/or magnitude of acquired immune
responses.
Methods
Unless specifically stated all materials and reagents were
purchased from Sigma-Aldrich (Singapore).
Cell culture
Human umbilical cord blood (CB) samples were col-
lected from normal full-term deliveries of informed indi-
viduals with formal consents, meeting the Universality
Institutional Review Board guidelines, for research using
human samples. CD34+ haematopoietic progenitor-cells
were harvested using MACS cell isolation kit (Miltenyi
Biotec), following the manufacturer's instructions.
The isolated CD34+ haematopoietic progenitor-cells were
cultured for 5-6-weeks in the presence of 100 ng/ml of
Stem Cell Factor (SCF Cat: 300-07, PeproTec, Rocky Hill,
NJ), and for the first week this was supplemented with 10
ng/ml of Interleukin-3 (IL-3 Cat: 200-03, PeproTec, Rocky
Hill, NJ). Cells were shown to be differentiated by staining
them for specific mast cell markers as follows: for mast
cells chymase, with an anti-human chymase mAb (IgG1-
MAB1254, Chemicon, Temecula, CA), and FITC-conju-
gated secondary antibody (anti-mouse IgG-FITC, Sigma-
Aldrich, Singapore); for c-Kit with anti-human c-Kit
mouse monoclonal PE-conjugated (Cat. No. 555714;
clone YB5.B8, BD Biosciences – Pharmigen, Singapore),
isotype control anti-mouse IgE-PE (Cat. No. 555749;
clone MOPC-21, BD Biosciences – Pharmigen, Singa-
pore); and for FcεRI cell-surface expression with anti-
human FcεRI polyclonal (Rabbit-IgG-ab31494; Abcam,
Cambridge, UK) and FITC-conjugated secondary anti-
body (anti-rabbit IgG-FITC, Sigma-Aldrich, Singapore)
also used as isotype control, and analyzed immediately
using a Coulter Epics-Elite ESP Flow Cytometer (Beck-
man, Germany). Purity was estimated at >97%. The differ-
entiated mast cells were plated in 6 well plates and
allowed to rest for 24 hr.
Mast cell stimulation and RNA extraction
After differentiation, mast cells were plated in 6 well plates
and allowed to rest for 24 hr. Cells in all wells, except the
control well, were sensitized with human monomeric IgEBMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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(1 µg/ml, IgE, Cat: 30-AI05, Lot number A01071004, Fit-
zgerald, Concord, MA) overnight. FcεRI aggregation was
carried out by incubating the cells with monoclonal
mouse-anti-human IgE (1 µg/ml, Anti-human-IgE, Cat:
MCA2115, clone 4C3, Serotec, Oxford, UK) at 37°C, for 2
hr, 6 hr and 12 hr. RNA was extracted from all the samples
using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA).
Integrity of RNA was checked by formamide gel electro-
phoresis; quantification of RNA was carried out by meas-
uring the A260 nm.
Labeling and hybridization
Labeling and hybridization was carried out as previously
described [46]. Briefly, 8 µg of total RNA from each sam-
ple was used to synthesize double stranded cDNA using
T7-(dT24) oligonucleotide primer and Superscript
Reverse transcriptase (Invitrogen). The resultant cDNA
was purified and 1 µg of purified cDNA was labeled with
biotin by transcription in vitro. The labeled cRNAs were,
fragmented in the presence of metal ions and then hybrid-
ized to HG-Focus array (Affymetrix), following hybridiza-
tion the gene chips were washed and stained after which
the chips were scanned by Gene Array Scanner (Agilent
technologies).
Microarray data collection and analysis
Data collection and analysis was carried out using Micro-
Array Suite 5.0 (MAS) (Affymetrix). The absolute data
(signal intensity, detection call and detection P-value)
were exported into GeneSpring v7.0 (Silicon Genetics,
Redwood City, CA, USA) software for analysis by para-
metric test based on cross gene error model (PCGEM). The
ANOVA approach has been used to find differentially
expressed genes (P < 0.05). The Benjamini and Hochberg
False Discovery Rate multiple testing correction was
applied.
Gene expression profile clustering
Agglomerative average-linkage hierarchical clustering of
the five different experimental were obtained for selected
groups of genes with Gene Spring 7.0 software (Silicon
Genetics, Redwood City, CA, USA) using standard correla-
tion as similarity matrix.
Real-time Quantitative PCR
Real-PCR was performed, as previously described [46],
using 1 µg of total RNA from the same samples used for
microarray experiments. PCR was performed for tran-
scripts of IL-1β (Primers: forward 5'-ATG GCA GAA GTA
CCT AAG CTC GC-3', reverse 5'-ACA CAA ATT GCA TGG
TGA AGT CAG TT-3'); IL-6 (Primers: forward 5'-ATG AAC
TCC TTC TCC ACA AGC GC-3', reverse 5' GAA GAG CCC
TCA GGC TGG ACT G-3'); IL-8 (Primers: forward 5'-ATG
ACT TCC AAG CTG GCC GTG GCT-3', reverse 5'TCT CAG
CCC TCT TCA AAA ACT TCT C-3'); MCP-3 (Primers: for-
ward 5'-TCC AAG GCT TTA TGT TCA AA-3', reverse 5'-
ACT GAA CTG AAA ACA AGC CA-3'); RANTES (Primers:
forward 5'-GCT GTC ATC CTC ATT GCT ACT G-3', reverse
5'-TCG AAC TCC TGA CCT CAA GTG ATC-3'); and for
SPHK1 (Primers: forward 5'-TGA ACC CGC GCG GCA
AGG GC-3', reverse 5'-GGT CAG CCG GCG CCA TCC
ACG-3').
For amplicon detection, the Light Cycler RNA Master
SYBR Green Kit (Roche) was used as described by the
manufacturer. PCRs were performed in a LightCycler®
instrument (Roche) as follows: reverse transcription at
61°C for 20 min, initial denaturation at 95°C for 2 min;
amplification for 45–65 cycles of denaturation (95°C, 5s,
ramp rate 20°C/s), annealing (optimal temperature, 5s,
ramp rate 20°C/s) and extension (72°C, product length
[bp]/25 s, ramp rate 2°C/s). A single online fluorescence
reading for each sample was taken at the end of extension
step. Quantitative results were expressed by identification
of the second derivative maximum points, which marked
the cycles where the second derivatives of the fluorescence
signal curves are at maximum. These points were
expressed as fractional cycle numbers. Then, these cycle
numbers were plotted against the logarithm of the con-
centrations of serially 2-fold diluted standard samples to
obtain a standard curve. The concentrations of unknown
samples were calculated by extrapolation from this stand-
ard curve. Positive sample specificity was confirmed by
determining the melting curve (95°C, 5s, ramp rate 20°C/
s; 68°C, 15s, ramp rate 20°C/s; 95°C, 0s, ramp rate
0.1°C/s, continuous measurement).
Cytokine detection
Supernatants from control cells, cells sensitized, and cells
following FcεRI aggregation, were collected and stored at
-20C until use. IL-1β, IL-6, IL-8, MCP-3 and RANTES lev-
els in the supernatants were evaluated using ELISA (R&D
Systems Inc., MN, USA) following the manufacturer's
instructions.
Gel electrophoresis and Western blots
Western blots were carried out as previously done [31].
Briefly, 40 µg of lysate for each sample was resolved on
10% polyacrylamide gels (SDS-PAGE) under denaturing
conditions and then transferred to 0.45 µm nitrocellulose
membranes.
For overall tyrosine phosphorytaion, the blots were
probed using a specific monoclonal anti-phosphotyrosine
primary antibody (P-Tyr, Sc-7020, Santa Cruz, CA, USA),
and an anti-mouse HRP-conjugated secondary antibody
(anti-mouse IgG-HRP, A-4416, Sigma). Bands were visu-
alized using the ECL Western Blotting Detection System
(Amersham, Singapore).BMC Genomics 2006, 7:210 http://www.biomedcentral.com/1471-2164/7/210
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For SPHK1 expression, the blots were probed using a rab-
bit polyclonal anti-SPHK1 primary antibody (anti-
SPHK1, X1627P, Exalpha, MA, USA), and HRP-conju-
gated secondary antibody (anti-rabbit IgG-HRP, sc-2004,
Santa Cruz, CA, USA). For loading control the blots were
probed with a monoclonal anti α-tubulin (anti-α-tubulin,
sc-5286, Santa Cruz, CA, USA), and an anti-mouse HRP-
conjugated secondary antibody (anti-mouse IgG-HRP, A-
4416, Sigma). Bands were visualized using the ECL West-
ern Blotting Detection System (Amersham, Singapore),
and quantified by densitometry analysis.
Cytosolic Ca2+
Cytosolic calcium was measured as described previously
[31]. Briefly, cells were loaded with 1 µg/ml Fura2-AM
(Molecular Probes, Leiden, The Netherlands) in PBS, 1.5
mM Ca2+ and 1 % BSA. After removal of excess reagents by
dilution and centrifugation (in PBS), the cells were resus-
pended in PBS containing 1.5 mM Ca2+ and 1 % BSA, for
30 min; or in PBS containing 1.5 mM Ca2+, 1 % BSA, and
human-monomeric IgE (1 µg/ml) for sensitization, for 30
min. After removal of excess IgE by dilution and centrifu-
gation (in PBS), the cells were resuspended in 1.5 mM
Ca2+  supplemented PBS and warmed to 37°C in the
cuvette; Unsensitazed cells were placed in the cuvette and
cytosolic calcium was measured before and after the addi-
tion of monomeric IgE. IgE-sensitized cells were placed in
the cuvette and FcεRI was crosslinked by addition of
mouse-anti-human IgE (1 µg/ml). Fluorescence was
measured at 340 and 380 nm.
β-hexosaminidase release
Degranulation was measured using as previously
described [31]. Briefly, an aliquot of cells was resus-
pended in PBS containing 1.5 mM Ca2+ and 1 % BSA, and
incubated with monomeric IgE for 30 min at 37°C.
Another aliquot of cells was resuspended in PBS contain-
ing human-monomeric IgE (1 µg/ml) for sensitization,
1.5 mM Ca2+ and 1 % BSA, for 30 min. After removal of
excess IgE by dilution and centrifugation (in PBS), the
cells were resuspended in 1.5 mM Ca2+ supplemented
PBS, and FcεRI was crosslinked by addition of mouse-
anti-human IgE (1 µg/ml) to cells for 30 min at 37°C.
Following the incubation, 50 µl of supernatant, was incu-
bated with 200 µl of 1 mM p-nitrophenyl N-acetyl-β-D-
glucosaminide for 1 hr at 37°C. The total β-hexosamini-
dase concentration was determined by a 1:1 extraction of
the remaining buffer and cells with 1% Triton X-100; a 50
µl aliquot was removed and analyzed as described. Reac-
tions were quenched by addition of 500 µl of 0.1 M
sodium carbonate buffer. The enzyme concentration was
determined by measuring the OD at 400 nm. β-hexosami-
nidase release was represented as a percent of total
enzyme.
Flow cytometry analysis for mast cell markers
To analyze the expression of the intracellular mast cell
chymase, 1 × 106cells were washed with ice cold PBS, fixed
and permeabilised using the FIX and PERM reagents from
Caltag (Caltag Laboratories, Burlingame, CA) as follows:
after washing, samples were resuspended in 100 ul of Rea-
gent A (Fixation medium) and incubated for 15 min at RT.
The cells were then washed twice with ice-cold PBS, and
resuspended in 100 ul of Reagent B (Permeabilization
medium) and incubated for 15 min at RT. Cells were
washed twice and resuspended in 100 µl of PBS/1% FBS
and 5 µl of the anti-human chymase mAb (IgG1-
MAB1254, Chemicon, Temecula, CA) was added and
samples were incubated for 20 min at RT. Samples were
washed twice in ice-cold PBS, then resuspended in PBS/
1% FBS and 5 µl of FITC-conjugated secondary antibody
(anti-mouse IgG-FITC, Sigma-Aldrich, Singapore) was
added, and incubated in dark for an 30 min at RT. Sam-
ples were washed twice with ice-cold PBS and resus-
pended in 100 µl of PBS/1% FBS for immediate analysis.
To analyze the cell surface expression of cKit and FceRI,
the samples were initially processed as above except that
the permeabilisation step was omitted. For c-Kit the pri-
mary antibody was an anti-human c-Kit mouse mono-
clonal (MCA1841, clone 104D2, Serotec, Oxford, UK),
and the secondary antibody was a FITC-conjugated (anti-
mouse IgG-FITC, Sigma-Aldrich, Singapore). For FcεRI
cell-surface expression, the cells were labeled with the pri-
mary anti-human FcεRI polyclonal (Rabbit-IgG-ab31494.
Abcam, Cambridge, UK), and the secondary antibody was
a FITC-conjugated (anti-rabbit IgG-FITC, Sigma-Aldrich,
Singapore). All the samples were analyzed by flow cytom-
etry was using a FACSCalibur machine (BD biosciences),
and the data analysed using the Cell Quest™ Pro Software.
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